Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022

Targeted protein degradation (TPD) is a promising therapeutic modality that has garnered attention in academic, industrial, and pharmaceutical research for treating diseases such as cancer, neurodegenerative disorders, inflammation, and viral infections. In this context, proteolysis-targeting chimer...

Full description

Bibliographic Details
Main Authors:	Rekha Tamatam, Dongyun Shin
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	targeted protein degradation proteolysis-targeting chimeras selectivity permeability linker flexibility
Online Access:	https://www.mdpi.com/1422-0067/24/6/5190

Similar Items

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
by: Yujeong Moon, et al.
Published: (2023-01-01)

Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design
by: Carlotta Cecchini, et al.
Published: (2022-04-01)

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
by: Robin Thomas Ulrich Haid, et al.
Published: (2023-01-01)

The clinical advances of proteolysis targeting chimeras in oncology
by: Hao Xie, et al.
Published: (2021-12-01)

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
by: André T. S. Vicente, et al.
Published: (2022-09-01)

Proteolysis-targeting chimeras and their implications in breast cancer
by: Angeles C. Tecalco-Cruz, et al.
Published: (2021-12-01)

Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras
by: Tianzhi Wen, et al.
Published: (2023-05-01)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
by: Salma Darwish, et al.
Published: (2022-07-01)

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
by: Shenxin Zeng, et al.
Published: (2021-03-01)

Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
by: Ke Ma, et al.
Published: (2021-01-01)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
by: Jingwei Shao, et al.
Published: (2021-10-01)

Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology
by: Carlotta Cecchini, et al.
Published: (2020-04-01)

Small-Molecule PROTACs for Cancer Immunotherapy
by: Zefan Liu, et al.
Published: (2022-08-01)

mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
by: Xiaoqi Xue, et al.
Published: (2024-02-01)

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
by: Mingchao Xiao, et al.
Published: (2022-09-01)

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
by: Carlotta Cecchini, et al.
Published: (2021-04-01)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
by: Rui Li, et al.
Published: (2022-12-01)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
by: Xinyi Li, et al.
Published: (2022-04-01)

Editorial: PROTACs: Targeted therapies for cancer treatment
by: Sobia Tabassum
Published: (2023-02-01)

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
by: Matthew R. Burke, et al.
Published: (2022-04-01)

Development of KEAP1-targeting PROTAC and its antioxidant properties: In vitro and in vivo
by: Se Yong Park, et al.
Published: (2023-08-01)

Applications of Bacterial Degrons and Degraders — Toward Targeted Protein Degradation in Bacteria
by: Matylda Anna Izert, et al.
Published: (2021-05-01)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
by: Rachael Arthur, et al.
Published: (2020-06-01)

Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma
by: Aishwarya Saraswat, et al.
Published: (2023-12-01)

Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies
by: Thi-Thao-Linh Nguyen, et al.
Published: (2022-03-01)

Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects
by: Hai‐Jun Liu, et al.
Published: (2023-06-01)

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
by: Siqi Wang, et al.
Published: (2024-01-01)

The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
by: Bernat Coll-Martínez, et al.
Published: (2020-12-01)

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
by: Pengyun Li, et al.
Published: (2023-06-01)

Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer
by: Giovanni L. Beretta, et al.
Published: (2019-05-01)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
by: Alberto Ocaña, et al.
Published: (2020-09-01)

Targeting androgen receptor degradation with PROTACs from bench to bedside
by: Xiaojuan Jia, et al.
Published: (2023-02-01)

Split‐Cas9‐based targeted gene editing and nanobody‐mediated proteolysis‐targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells
by: Changping Deng, et al.
Published: (2023-08-01)

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
by: Patrizia Porazzi, et al.
Published: (2021-08-01)

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
by: Bohan Ma, et al.
Published: (2022-10-01)

Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01)

Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity
by: Friedrich Hahn, et al.
Published: (2021-11-01)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
by: Chao Wang, et al.
Published: (2022-12-01)

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
by: Xuyang Zhao, et al.
Published: (2023-04-01)

Current strategies for the design of PROTAC linkers: a critical review
by: Robert I. Troup, et al.
Published: (2020-10-01)